Relapsed / refractory MDS

Clinical trials for Relapsed / refractory MDS explained in plain language.

Never miss a new study

Get alerted when new Relapsed / refractory MDS trials appear

Sign up with your email to follow new studies for Relapsed / refractory MDS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New Antibody-Drug conjugate takes aim at tough leukemias

Disease control Ongoing

This first-in-human trial tests BYON4413, an antibody-drug conjugate designed to target and kill cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS). The study involves 16 participants and aims to check safety, how th…

Matched conditions: RELAPSED / REFRACTORY MDS

Phase 1 • Sponsor: Byondis B.V. • Aim: Disease control

Last updated Jun 27, 2026 08:13 UTC

Relapsed / refractory MDS

Get alerted when new Relapsed / refractory MDS trials appear

New Antibody-Drug conjugate takes aim at tough leukemias